Reference entry · Long-acting GHRH analog
CJC-1295 (with DAC)
Also known as: Modified GRF(1-29) with DAC · Drug Affinity Complex
- Class
- Long-acting GHRH analog
- Primary targets (literature)
- GHRH receptor
- Regulatory context
- Not FDA-approved. Two CJC-1295 variants (DAC vs. no DAC) require explicit catalog specification.
Overview
CJC-1295 with DAC is a GHRH analog modified for extended exposure via albumin-binding chemistry. Pharmacokinetics differ substantially from the no-DAC form — they are separate research materials, not interchangeable vials.
Mechanism in research literature
GHRH receptor activation stimulates pituitary GH release. DAC modification prolongs half-life by reducing clearance compared with native GRF(1-29) sequences.
Common research focus areas
- Extended GH and IGF-1 elevation in research protocols
- DAC chemistry and albumin binding
- Distinction from no-DAC analog
- Combination interest with ghrelin mimetics
Full literature roundup
Read the cited research summary
A long-acting GHRH analog with Drug Affinity Complex modification. Pharmacokinetic research, literature, and documentation notes.
CJC-1295 (with DAC) research roundup · 5 minEvaluate catalog material
- COA literacy — read batch documentation before comparing vendors.
- Peptide identity testing — why sequence confirmation matters beyond purity %.
- How we vet sources — our score methodology for recommended vendors.